[Skip to Content]
[Skip to Content Landing]
March 22, 1965

Recalcitrant Urinary-Tract InfectionsTreatment With Intravenous Oxytetracycline Hydrochloride

Author Affiliations

From the Infectious Disease Research Laboratory, Veterans Administrations Hospital, Batavia, NY.

JAMA. 1965;191(12):1029-1031. doi:10.1001/jama.1965.03080120063025

MORE FREQUENT recognition of urinary-tract infections has occurred in recent years. Unsuspected serious kidney infections have often been discovered only when severe renal damage was found at autopsy.1 The frequency of cures of severe genitourinary-tract infections has not paralleled the increasing numbers of antibacterial agents available for treatment. The experience of most clinicians and microbiologists indicates that the causative agents of such infections are resistant to a larger spectrum of antibacterial drugs.2 It is neither surprising nor uncommon to encounter strains of Pseudomonas, Proteus, and Aerobacter which are resistant to all antibiotics tested by the disk sensitivity method. When such a situation arises, the availability of an antimicrobial agent which could safely reach bactericidal levels in the patient, even though a sensitivity test showed a significant degree of resistance, would be highly desirable. Intravenous oxytetracycline hydrochloride (Terramycin) appears to possess some of the desirable characteristics for such therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview